T1	Participants 58 111	patients with relapsing-remitting multiple sclerosis:
T2	Participants 584 613	51 centres in nine countries.
T3	Participants 756 843	720 patients screened, 306 eligible patients were enrolled. Patients, aged 18-50 years,